Semaglutide — the molecule sold as Ozempic and Wegovy — extended the lifespan of old but otherwise healthy female mice by a median of roughly 100 days, while improving their memory, muscle function and blood-sugar control. The finding, published in Nature, is notable less for the size of the effect than for the setting: the animals were not obese and not diabetic, and treatment began late in life.
What exactly did the study do?
A team led by Danica Chen, Ph.D., professor of metabolic biology and nutrition at UC Berkeley, with collaborators at the University of Copenhagen and the National Institute on Aging (NIA), ran two experiments in female mice.
In the first, treatment started at 20 months of age — roughly the equivalent of a human in their sixties — and ran for three months, with a separate cohort dosed until natural death so lifespan could be measured. In the second, a five-month experiment pitted semaglutide directly against 24% calorie restriction, the oldest and most reliable life-extending intervention in laboratory animals, with dietary intake matched between the groups so the comparison was fair.
The paper is Late-life semaglutide treatment slows ageing and extends lifespan in female mice (Feng et al., Nature 657:469, 2026), funded by NIA grants and accompanied by commentary from the NIA’s Rafael de Cabo, Ph.D.
What improved?
Treated mice showed better muscle function, better spatial memory and more exploratory behavior, and they held onto glucose control that normally erodes with age. Underneath the behavior, the researchers saw reduced inflammation, less decline in tissue regenerative capacity, and gene-activity signatures of aging that were blunted relative to untreated controls. The median lifespan gain in the treated-until-death cohort was about 100 days.
Is this just calorie restriction in a syringe?
That is the obvious objection — GLP-1 drugs suppress appetite, and eating less is already known to extend rodent lifespan. The head-to-head experiment was designed to answer it, and the answer appears to be no, not entirely.
Semaglutide reproduced many of the effects of calorie restriction, but outperformed it on exploratory behavior and spatial memory. The most telling divergence was metabolic: calorie-restricted mice slowed their metabolic rate, the classic adaptive response to less food, while semaglutide-treated mice maintained theirs. If the drug were simply a chemical form of dieting, the two curves should have tracked each other.
“These differences point to the possibility that GLP-1 drugs tap into a biological pathway independent of calorie restriction,” Chen said. “Uncovering this potential route and the benefits that may specifically stem from it is an important direction for future research.”
Why geroscientists care about the timing
Most interventions that extend life in mice — rapamycin, various genetic knockouts, calorie restriction itself — work best when started early, which limits how relevant they are to a 65-year-old human. An intervention that still works when begun at the rodent equivalent of late middle age is a much better fit for how medicine is actually delivered. That is the practical significance of the late-life dosing here.
It also lands in a field that has been searching for a drug it can take into human trials. Metformin has been the perennial candidate; rapamycin analogues have had mixed results; senolytics remain early. GLP-1 receptor agonists arrive with an enormous safety database and tens of millions of people already taking them — which would make an aging indication unusually tractable, if the biology holds.
What this does not show
It does not show that Ozempic or Wegovy extends human life. There is no clinical evidence for that, and the study makes no such claim. Several specific limits are worth stating plainly:
The work was done in female mice only. Sex-specific results are common in aging research and sometimes disappear in the other sex, so the male data are a genuine open question. Mouse lifespan studies are also sensitive to strain, diet and housing, and effects that look robust in one laboratory can shrink in another. Dose scaling from mice to people is not straightforward. And in humans, GLP-1 therapy is associated with loss of lean mass alongside fat — a real concern if the goal were to preserve function in older adults rather than to treat obesity.
What happens next
Chen framed the ambition directly: “We are very excited by this new study, because it could potentially broaden the application of GLP-1 medicines to healthy aging individuals to extend lifespan.” The realistic next steps are mechanistic — identifying the calorie-restriction-independent pathway — and, eventually, carefully designed studies in healthy older adults without obesity or diabetes, a population these drugs have never been tested in.
Until then this is an interesting mouse result with an unusually good rationale for following up. Preclinical research; not medical advice. Do not start or change a prescription medication based on animal studies.